UNSPSC 51421702: Corticorelin

This classification denotes a crh gene with the molecular formula C208H344N60O63S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 305OE8862Y, chemically known as l-alaninamide, l-seryl-l-glutaminyl-l-alpha-glutamyl-l-prolyl-l-prolyl-l-isoleucyl-l-seryl-l-leucyl-l-alpha-aspartyl-l-leucyl-l-threonyl-l-phenylalanyl-l-histidyl-l-leucyl-l-leucyl-l-arginyl-l-alpha-glutamyl-l-valyl-l-leucyl-l-alpha-glutamyl-l-methionyl-l-thronyl-l-lysyl-l-alanyl-l-alpha-aspartyl-l-glutaminyl-l-leucyl-l-alanyl-l-glutaminyl-l-glutaminyl-l-alanyl-l-histidyl-l-seryl-l-asparaginyl-l-arginyl-l-lysyl-l-leucyl-l-leucyl-l-alpha-aspartyl-l-isoleucyl- but generally known as corticorelin, which bears US NIH Compound Identifier 16132344.

UNSPSC 51421702 Corticorelin is a Commodity code that in practice captures pharmaceutical and medical supplies procured by state and local health agencies, though the recent opportunity record shows a mismatch between the code's nominal scope and actual buying activity. The single recent solicitation under this code — Seminole County, Florida's IFB60459723LAS — seeks Naloxone and Safe Drug Deactivation Systems rather than corticorelin, suggesting the code may be misapplied or the taxonomy does not cleanly partition opioid-antagonist and drug-disposal supplies. State and local health departments and county community health offices appear to be the primary issuing bodies, driven by public-health emergency response and harm-reduction mandates that have accelerated procurement of overdose-reversal and controlled-substance management tools in recent years.

Seminole County's July 2026 solicitation represents the most recent tracked activity, an IFB seeking annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract carries a two-year initial term with one-year renewal option, fixed-fee pricing, E-Verify compliance, and potential FEMA funding with associated federal regulatory obligations. The limited recent-opportunity record under this code suggests either sparse activity, chronic miscoding by issuing bodies, or a shift in how state and local procurement offices classify pharmaceutical and emergency-response supplies. Firms pursuing this code should verify current taxonomy alignment with target accounts before investing in pre-bid engagement.